viewTiziana Life Sciences PLC

Tiziana Life Sciences expands its oncology pipeline into CART-T therapy space

Chief executive Dr Kunwar Shailubhai and his team believe an improved CAR-T therapy can be achieved through using anti-CD3 monoclonal antibodies such as Foralumab on its own or with other “co-stimulatory molecules”

Tiziana Life Sciences PLC -

Tiziana Life Sciences PLC (LON:TLSA) (NASDAQ:TILS) has submitted a patent application that could help unlock the true potential of a promising form of cancer immunotherapy.

It wants to use Foralumab, its fully human anti-CD3 monoclonal antibody, to improve the success of CAR-T therapy.

CAR-T uses T cells from the patient’s own immune system to tackle the disease. Simply put, they are genetically engineered and “supercharged” to hunt down and destroy cancer cells.

The major problem with the approach is relapse rates are high, limiting the scope of its use.

Tiziana chief executive Dr Kunwar Shailubhai and his team believe an improved CAR-T therapy can be achieved through using anti-CD3 monoclonal antibodies such as Foralumab on its own or with other “co-stimulatory molecules”.

“Being a fully human anti-CD3 mAb, Foralumab is most suitable for CAR-T therapy as it does not produce an immune response unlike other humanised anti-CD3 mAbs,” explained Shailubhai in a statement.

Nkarta IPO reveals interest in CAR-T

Despite its limitations, CAR-T is a hot area at the moment, underlined by the explosive NASDAQ IPO of Nkarta Inc (NASDAQ:NKTX).

Listed at US$18 a share, stock in the Bay area-based biotech raced to US$$58.69 on the first day of trading earlier this week, valuing the business at just shy of US$1.8bn.

The listing brought in almost US$290mln in new funding for a business that currently has no drug in the clinic. Investors include RA Capital, New Enterprise Associates, Novo and GlaxoSmithKline.

Foralumab, meanwhile, is currently being developed for Crohn’s Disease and progressive multiple sclerosis.

The company is far from a one-trick pony, though Foralumab is fast emerging as the jewel in the crown for the group, which has clinical and pre-clinical assets spanning cancers, autoimmune and inflammatory diseases.

COVID 'kicker' 

It is “aggressively advancing” a potential treatment for coronavirus (COVID-19) alongside a breakthrough method of delivering the inhaled version of this and other similar drugs.

And it is planning to spin out its diagnostics business StemPrintER.

“In our view, StemPrintER could begin trading as a separate entity well before the end of this year,” said HC Wainwright’s Raghuram Selvaraju in a recent note repeating his ‘buy’ recommendation and US$25 a share price target.

In the US, the stock closed at US$8.63.


Quick facts: Tiziana Life Sciences PLC

Price: 83.6 GBX

Market: AIM
Market Cap: £162.7 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tiziana Life Sciences PLC named herein, including the promotion by the Company of Tiziana Life Sciences PLC in any Content on the Site, the...


Market report: FTSE calms as optimism vaccine news is challenged by rise in...

FTSE 100 had a lukewarm start on Wednesday as positive vaccine news can’t change the current rise in infections and global lockdowns. London’s leading index advanced 11 points to 6,308 in early dealing. JD Wetherspoon PLC (LON:JDW) has posted a 28% slump in sales over the past four months...

3 weeks, 1 day ago

2 min read